82 FR 56976 - Barr Laboratories, Inc. et al.; Withdrawal of Approval of 68 Abbreviated New Drug Applications
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration Federal Register Volume 82, Issue 230 (December 1, 2017)
Food and Drug Administration
Federal Register Volume 82, Issue 230 (December 1, 2017)
| Page Range | 56976-56978 | |
| FR Document | 2017-25920 |
[Federal Register Volume 82, Number 230 (Friday, December 1, 2017)] [Notices] [Pages 56976-56978] From the Federal Register Online [www.thefederalregister.org] [FR Doc No: 2017-25920] ----------------------------------------------------------------------- DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration [Docket No. FDA-2017-N-6591] Barr Laboratories, Inc. et al.; Withdrawal of Approval of 68 Abbreviated New Drug Applications AGENCY: Food and Drug Administration, HHS. ACTION: Notice. ----------------------------------------------------------------------- SUMMARY: The Food and Drug Administration (FDA or Agency) is withdrawing approval of 68 abbreviated new drug applications (ANDAs) from multiple applicants. The holders of the applications notified the Agency in writing that the drug products were no longer marketed and requested that the approval of the applications be withdrawn. DATES: Approval is withdrawn as of January 2, 2018. FOR FURTHER INFORMATION CONTACT: Trang Tran, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 75, Rm. 1671, Silver Spring, MD 20993-0002, 240-402-7945. SUPPLEMENTARY INFORMATION: The holders of the applications listed in table 1 in this document have informed FDA that these drug products are no longer marketed and have requested that FDA withdraw approval of the applications under the process in Sec. 314.150(c) (21 CFR 314.150(c)). The applicants have also, by their requests, waived their opportunity for a hearing. Withdrawal of approval of an application or abbreviated application under Sec. 314.150(c) is without prejudice to refiling. Table 1 ------------------------------------------------------------------------ Application No. Drug Applicant ------------------------------------------------------------------------ ANDA 040135............... Estropipate Tablets Barr Laboratories, USP, 0.75 milligrams Inc., Subsidiary of (mg), 1.5 mg, and 3 Teva Pharmaceuticals mg. USA, Inc., 425 Privet Rd., Horsham, PA 19044. ANDA 040755............... Carisoprodol Tablets Sun Pharmaceutical USP, 350 mg. Industries, Ltd., c/ o Sun Pharmaceutical Industries, Inc., 270 Prospect Plains Rd., Cranbury, NJ 08512. [[Page 56977]] ANDA 062588............... Gentamicin Sulfate in Hospira, Inc., a 0.9% Sodium Chloride Pfizer Company, 275 Injection, North Field Dr., Equivalent to (EQ) Bldg. H1, Lake 1.2 mg base/ Forest, IL 60045. milliliter (mL), EQ 1.4 mg base/mL, EQ 1.6 mg base/mL, EQ 1.8 mg base/mL, EQ 2 mg base/mL, EQ 60 mg base/100 mL, EQ 70 mg base/100 mL, EQ 80 mg base/100 mL, EQ 90 mg base/100 mL, and EQ 100 mg base/100 mL. ANDA 062591............... Kefurox (cefuroxime) ACS Dobfar S.p.A., c/ for Injection USP, o Interchem Corp., EQ 750 mg base/vial, 120 Route 17 North, EQ 1.5 grams (g) Paramus, NJ 07652. base/vial, and EQ 7.5 g base/vial. ANDA 062756............... Primaxin IV (imipenem Merck Sharp & Dohme and cilastatin) for Corp., Subsidiary of Injection USP, 250 Merck & Co., Inc., 1 mg/vial; EQ 250 mg Merck Dr., P.O. Box base/vial and 500 mg/ 100, Whitehouse vial; EQ 500 mg base/ Station, NJ 08889. vial. ANDA 063207............... Cefazolin for Facta Farmaceutici Injection USP, EQ 1 S.p.A., c/o g base/vial. Interchem Corp., 120 Route 17 North, Suite 115, Paramus, NJ 07652. ANDA 063209............... Cefazolin for Do. Injection USP, EQ 10 g base/vial and EQ 20 g base/vial (Pharmacy Bulk Package). ANDA 063214............... Cefazolin for Do. Injection USP, EQ 500 mg base/vial. ANDA 063263............... Amikacin Sulfate Hospira, Inc. Injection USP, EQ 50 mg base/mL. ANDA 065268............... Ceftriaxone for Facta Farmaceutici Injection USP, EQ 1 S.p.A. g base/vial and EQ 2 g base/vial. ANDA 065269............... Ceftriaxone for Do. Injection USP, EQ 10 g base/vial (Pharmacy Bulk Package). ANDA 065348............... Cefotaxime for Cephazone Pharma, Injection USP, EQ 10 LLC, 250 E. Bonita g base/vial Ave., Pomona, CA (Pharmacy Bulk 91767. Package). ANDA 065464............... Cefoxitin for ACS Dobfar S.p.A. Injection USP, EQ 10 g base/vial (Pharmacy Bulk Package). ANDA 065467............... Cefoxitin for Do. Injection USP, EQ 1 g base/vial and EQ 2 g base/vial. ANDA 070048............... Cotrim D.S. Teva Pharmaceuticals (sulfamethoxazole USA, Inc., 425 and trimethoprim) Privet Rd., Horsham, Tablets USP, 800 mg/ PA 19044. 160 mg. ANDA 070195............... Valproic Acid Catalent Pharma Capsules USP, 250 mg. Solutions, LLC, 2725 Scherer Dr. North, St. Petersburg, FL 33716. ANDA 070513............... Tolazamide Tablets Watson Laboratories, USP, 100 mg. Inc., Subsidiary of Teva Pharmaceuticals USA, Inc., 425 Privet Rd., Horsham, PA 19044. ANDA 070514............... Tolazamide Tablets Do. USP, 250 mg. ANDA 071358............... Tolazamide Tablets Sun Pharmaceutical USP, 250 mg. Industries, Inc., 270 Prospect Plains Rd., Cranbury, NJ 08512. ANDA 071359............... Tolazamide Tablets Do. USP, 500 mg. ANDA 071667............... Ibuprofen Tablets Pliva, Inc., USP, 600 mg. Subsidiary of Teva Pharmaceuticals USA, Inc., 425 Privet Rd., Horsham, PA 19044. ANDA 071668............... Ibuprofen Tablets Do. USP, 800 mg. ANDA 071735............... Ibuprofen Tablets Contract Pharmacal USP, 200 mg. Corp., c/o SciRegs International Inc., 6333 Summercrest Dr., Columbia, MD 21045. ANDA 071773............... Ibuprofen Tablets Pliva, Inc., USP, 200 mg. Subsidiary of Teva Pharmaceuticals USA, Inc. ANDA 073254............... Loperamide Contract Pharmacal Hydrochloride (HCl) Corp. Tablets USP, 2 mg. ANDA 074075............... Clemastine Fumarate Actavis Mid Atlantic, Syrup, EQ 0.5 mg LLC, Subsidiary of base/5 mL. Teva Pharmaceuticals USA, Inc., 425 Privet Rd., Horsham, PA 19044. ANDA 074536............... Haloperidol Oral Do. Solution USP, EQ 1 mg base/mL. ANDA 074782............... Ibuprofen Capsules, Contract Pharmacal 200 mg. Corp. ANDA 074789............... Naproxen Sodium Do. Tablets USP, EQ 200 mg base. ANDA 074931............... Ibuprofen Tablets Do. USP, 200 mg. ANDA 074961............... Cimetidine Tablets Do. USP, 200 mg. ANDA 074963............... Cimetidine Tablets Do. USP, 200 mg. ANDA 075094............... Ranitidine Tablets Do. USP, EQ 75 mg base. ANDA 075588............... Ibuprofen and Do. Pseudoephedrine HCl Tablets USP, 200 mg/ 30 mg. ANDA 077058............... Pantoprazole Sodium Sun Pharmaceutical Delayed-Release Industries, Ltd. Tablets USP, EQ 20 mg base and EQ 40 mg base. ANDA 077172............... Ondansetron Injection Do. USP, EQ 2 mg base/mL. ANDA 077329............... Octreotide Acetate Do. Injection, EQ 0.05 mg base/mL, EQ 0.1 mg base/mL, and EQ 0.5 mg base/mL. ANDA 077330............... Octreotide Acetate Do. Injection, EQ 0.2 mg base/mL. ANDA 077331............... Octreotide Acetate Do. Injection, EQ 1 mg base/mL. ANDA 078108............... Sertraline HCl Do. Tablets, EQ 25 mg base, EQ 50 mg base, and EQ 100 mg base. ANDA 078478............... Torsemide Tablets, 5 Do. mg, 10 mg, 20 mg, and 100 mg. ANDA 083000............... Folic Acid Tablets, 1 Ivax Pharmaceutical mg. USA, Inc., Subsidiary of Teva Pharmaceuticals USA, Inc., 425 Privet Rd., Horsham, PA 19044. ANDA 085549............... Reserpine, Watson Laboratories, Hydralazine HCl, and Inc., Subsidiary of Hydrochlorothiazide Teva Pharmaceuticals Tablets, 0.1 mg/25 USA, Inc. mg/15 mg. ANDA 086109............... Tolbutamide Tablets Do. USP, 500 mg. ANDA 086577............... Trimethobenzamide HCl Do. Injection, 100 mg/mL. [[Page 56978]] ANDA 087191............... Triamcinolone Alpharma U.S. Pharms, Acetonide Lotion Subsidiary of Teva USP, 0.025%. Pharmaceuticals USA, Inc., 425 Privet Rd., Horsham, PA 19044. ANDA 087398............... Spironolactone and Watson Laboratories, Hydrochlorothiazide Inc., Subsidiary of Tablets USP, 25 mg/ Teva Pharmaceuticals 25 mg. USA, Inc. ANDA 088229............... Thioridazine HCl Oral Actavis Mid Atlantic, Solution USP, 100 mg/ LLC, Subsidiary of mL. Teva Pharmaceuticals USA, Inc. ANDA 088563............... Thioridazine HCl Watson Laboratories, Tablets USP, 50 mg. Inc., Subsidiary of Teva Pharmaceuticals USA, Inc. ANDA 088567............... Thioridazine HCl Do. Tablets USP, 25 mg. ANDA 088733............... Meclizine HCl Pliva, Inc., Tablets, 25 mg Subsidiary of Teva (Chewable). Pharmaceuticals USA, Inc. ANDA 088869............... Thioridazine HCl Watson Laboratories, Tablets USP, 150 mg. Inc., Subsidiary of Teva Pharmaceuticals USA, Inc. ANDA 090800............... Quinapril Tablets Sun Pharmaceutical USP, EQ 5 mg base, Industries, Ltd. EQ 10 mg base, EQ 20 mg base, and EQ 40 mg base. ANDA 091177............... Anastrozole Tablets, Do. 1 mg. ANDA 091466............... Letrozole Tablets Do. USP, 2.5 mg. ANDA 200486............... Norethindrone and Mylan Laboratories, Ethinyl Estradiol Ltd., c/o Mylan Tablets USP, 0.5 mg/ Pharmaceuticals, 0.035 mg, 0.75 mg/ Inc., 781 Chestnut 0.035 mg, and 1 mg/ Ridge Rd., P.O. Box 0.035 mg. 4310, Morgantown, WV 26504. ANDA 200488............... Norethindrone and Do. Ethinyl Estradiol Tablets USP, 0.5 mg/ 0.035 mg. ANDA 200489............... Norethindrone and Do. Ethinyl Estradiol Tablets USP, 1 mg/ 0.035 mg. ANDA 201250............... Vancomycin HCl for Teva Pharmaceuticals Injection USP, EQ 5 USA, Inc. g base/vial and EQ 10 g base/vial (Pharmacy Bulk Package). ANDA 201251............... Vancomycin HCl for Do. Injection USP, EQ 500 mg base/vial and EQ 1 g base/vial. ANDA 201828............... Norgestrel and Mylan Laboratories, Ethinyl Estradiol Ltd. Tablets USP, 0.3 mg/ 0.03 mg. ANDA 202203............... Topotecan HCl for Sun Pharmaceutical Injection, EQ 4 mg Industries, Ltd. base/vial. ANDA 202746............... Zoledronic Acid Sun Pharma Global Injection, EQ 4 mg FZE, c/o Sun base/5 mL. Pharmaceutical Industries, Inc., 2 Independence Way, Princeton, NJ 08540. ANDA 202875............... Norgestrel and Mylan Laboratories, Ethinyl Estradiol Ltd. Tablets USP, 0.5 mg/ 0.05 mg. ANDA 203476............... Zolmitriptan Tablets, Sun Pharma Global 2.5 mg and 5 mg. FZE. ANDA 203685............... Irbesartan Tablets Ajanta Pharma Ltd., c/ USP, 75 mg, 150 mg, o Ajanta Pharma USA, and 300 mg. Inc., One Grande Commons, 440 US Highway 22 East, Suite 150, Bridgewater, NJ 08807. ANDA 203838............... Hydrocodone Tris Pharma, Inc., Bitartrate, 2033 Route 130, Chlorpheniramine Monmouth Junction, Maleate, and NJ 08852. Pseudoephedrine HCl Oral Solution, 5 mg/ 4 mg/60 mg per 5 mL. ANDA 203839............... Hydrocodone Do. Bitartrate and Pseudoephedrine HCl Oral Solution, 5 mg/ 60 mg per 5 mL. ------------------------------------------------------------------------ Therefore, approval of the applications listed in table 1 of this document, and all amendments and supplements thereto, is hereby withdrawn as of January 2, 2018. Introduction or delivery for introduction into interstate commerce of products without approved new drug applications violates section 301(a) and (d) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 331(a) and (d)). Drug products that are listed in table 1 that are in inventory on the date that this notice becomes effective (see the DATES section) may continue to be dispensed until the inventories have been depleted or the drug products have reached their expiration dates or otherwise become violative, whichever occurs first. Dated: November 27, 2017. Leslie Kux, Associate Commissioner for Policy.. [FR Doc. 2017-25920 Filed 11-30-17; 8:45 am] BILLING CODE 4164-01-P
![56976 Federal Register / Vol. 82, No. 230 / Friday, December 1, 2017 / Notices
and other applicable disclosure law. For location of the advisory committee public conduct during advisory
more information about FDA’s posting meeting, and the background material committee meetings.
of comments to public dockets, see 80 will be posted on FDA’s Web site after Notice of this meeting is given under
FR 56469, September 18, 2015, or access the meeting. Background material is the Federal Advisory Committee Act (5
the information at: https://www.gpo.gov/ available at https://www.fda.gov/ U.S.C. app. 2).
fdsys/pkg/FR-2015-09-18/pdf/2015- AdvisoryCommittees/Calendar/ Dated: November 24, 2017.
23389.pdf. default.htm. Scroll down to the Leslie Kux,
Docket: For access to the docket to appropriate advisory committee meeting
read background documents or the Associate Commissioner for Policy.
link.
electronic and written/paper comments [FR Doc. 2017–25911 Filed 11–30–17; 8:45 am]
Procedure: Interested persons may
received, go to https://www. present data, information, or views,
BILLING CODE 4164–01–P
regulations.gov and insert the docket orally or in writing, on issues pending
number, found in brackets in the before the committee. All electronic and
heading of this document, into the DEPARTMENT OF HEALTH AND
written submissions submitted to the HUMAN SERVICES
‘‘Search’’ box and follow the prompts Docket (see ADDRESSES) on or before
and/or go to the Dockets Management
December 27, 2017, will be provided to Food and Drug Administration
Staff, 5630 Fishers Lane, Rm. 1061,
the committee. Oral presentations from
Rockville, MD 20852. [Docket No. FDA–2017–N–6591]
the public will be scheduled between
FOR FURTHER INFORMATION CONTACT: approximately 1:30 p.m. and 2:30 p.m.
Lauren D. Tesh, Center for Drug Barr Laboratories, Inc. et al.;
Those individuals interested in making
Evaluation and Research, Food and Withdrawal of Approval of 68
formal oral presentations should notify
Drug Administration, 10903 New Abbreviated New Drug Applications
the contact person and submit a brief
Hampshire Ave., Bldg. 31, Rm. 2417, statement of the general nature of the AGENCY: Food and Drug Administration,
Silver Spring, MD 20993–0002, 301– evidence or arguments they wish to HHS.
796–9001, Fax: 301–847–8533, email: present, the names and addresses of
AMDAC@fda.hhs.gov, or FDA Advisory ACTION: Notice.
proposed participants, and an
Committee Information Line, 1–800– indication of the approximate time SUMMARY: The Food and Drug
741–8138 (301–443–0572 in the requested to make their presentation on Administration (FDA or Agency) is
Washington, DC area). A notice in the or before December 18, 2017. Time withdrawing approval of 68 abbreviated
Federal Register about last minute allotted for each presentation may be new drug applications (ANDAs) from
modifications that impact a previously limited. If the number of registrants multiple applicants. The holders of the
announced advisory committee meeting requesting to speak is greater than can applications notified the Agency in
cannot always be published quickly be reasonably accommodated during the writing that the drug products were no
enough to provide timely notice. scheduled open public hearing session, longer marketed and requested that the
Therefore, you should always check the FDA may conduct a lottery to determine approval of the applications be
Agency’s Web site at https:// the speakers for the scheduled open withdrawn.
www.fda.gov/AdvisoryCommittees/ public hearing session. The contact
default.htm and scroll down to the DATES: Approval is withdrawn as of
person will notify interested persons January 2, 2018.
appropriate advisory committee meeting regarding their request to speak by
link, or call the advisory committee December 19, 2017. FOR FURTHER INFORMATION CONTACT:
information line to learn about possible Trang Tran, Center for Drug Evaluation
modifications before coming to the Persons attending FDAs advisory and Research, Food and Drug
meeting. committee meetings are advised that the Administration, 10903 New Hampshire
Agency is not responsible for providing Ave., Bldg. 75, Rm. 1671, Silver Spring,
SUPPLEMENTARY INFORMATION: access to electrical outlets.
Agenda: The committee will discuss MD 20993–0002, 240–402–7945.
new drug application (NDA) 210693, FDA welcomes the attendance of the SUPPLEMENTARY INFORMATION: The
ciprofloxacin dispersion for inhalation, public at its advisory committee holders of the applications listed in
sponsored by Aradigm Corp., for the meetings and will make every effort to table 1 in this document have informed
proposed indication of treatment of non- accommodate persons with disabilities. FDA that these drug products are no
cystic fibrosis bronchiectasis patients If you require special accommodations longer marketed and have requested that
with chronic lung infections with due to a disability, please contact FDA withdraw approval of the
Pseudomonas aeruginosa. Lauren D. Tesh at least 7 days in applications under the process in
FDA intends to make background advance of the meeting. § 314.150(c) (21 CFR 314.150(c)). The
material available to the public no later FDA is committed to the orderly applicants have also, by their requests,
than 2 business days before the meeting. conduct of its advisory committee waived their opportunity for a hearing.
If FDA is unable to post the background meetings. Please visit our Web site at Withdrawal of approval of an
material on its Web site prior to the https://www.fda.gov/Advisory application or abbreviated application
meeting, the background material will Committees/AboutAdvisoryCommittees/ under § 314.150(c) is without prejudice
be made publicly available at the ucm111462.htm for procedures on to refiling.
TABLE 1
sradovich on DSK3GMQ082PROD with NOTICES
Application No. Drug Applicant
ANDA 040135 ......... Estropipate Tablets USP, 0.75 milligrams (mg), 1.5 mg, Barr Laboratories, Inc., Subsidiary of Teva Pharmaceuticals
and 3 mg. USA, Inc., 425 Privet Rd., Horsham, PA 19044.
ANDA 040755 ......... Carisoprodol Tablets USP, 350 mg ...................................... Sun Pharmaceutical Industries, Ltd., c/o Sun Pharma-
ceutical Industries, Inc., 270 Prospect Plains Rd.,
Cranbury, NJ 08512.
VerDate Sep<11>2014 16:44 Nov 30, 2017 Jkt 244001 PO 00000 Frm 00036 Fmt 4703 Sfmt 4703 E:\FR\FM\01DEN1.SGM 01DEN1](https://thefederalregister.org/doc/82_FR_57206/page/1.svg)
![56978 Federal Register / Vol. 82, No. 230 / Friday, December 1, 2017 / Notices
TABLE 1—Continued
Application No. Drug Applicant
ANDA 087191 ......... Triamcinolone Acetonide Lotion USP, 0.025% ..................... Alpharma U.S. Pharms, Subsidiary of Teva Pharma-
ceuticals USA, Inc., 425 Privet Rd., Horsham, PA 19044.
ANDA 087398 ......... Spironolactone and Hydrochlorothiazide Tablets USP, 25 Watson Laboratories, Inc., Subsidiary of Teva Pharma-
mg/25 mg. ceuticals USA, Inc.
ANDA 088229 ......... Thioridazine HCl Oral Solution USP, 100 mg/mL ................. Actavis Mid Atlantic, LLC, Subsidiary of Teva Pharma-
ceuticals USA, Inc.
ANDA 088563 ......... Thioridazine HCl Tablets USP, 50 mg .................................. Watson Laboratories, Inc., Subsidiary of Teva Pharma-
ceuticals USA, Inc.
ANDA 088567 ......... Thioridazine HCl Tablets USP, 25 mg .................................. Do.
ANDA 088733 ......... Meclizine HCl Tablets, 25 mg (Chewable) ............................ Pliva, Inc., Subsidiary of Teva Pharmaceuticals USA, Inc.
ANDA 088869 ......... Thioridazine HCl Tablets USP, 150 mg ................................ Watson Laboratories, Inc., Subsidiary of Teva Pharma-
ceuticals USA, Inc.
ANDA 090800 ......... Quinapril Tablets USP, EQ 5 mg base, EQ 10 mg base, Sun Pharmaceutical Industries, Ltd.
EQ 20 mg base, and EQ 40 mg base.
ANDA 091177 ......... Anastrozole Tablets, 1 mg .................................................... Do.
ANDA 091466 ......... Letrozole Tablets USP, 2.5 mg ............................................. Do.
ANDA 200486 ......... Norethindrone and Ethinyl Estradiol Tablets USP, 0.5 mg/ Mylan Laboratories, Ltd., c/o Mylan Pharmaceuticals, Inc.,
0.035 mg, 0.75 mg/0.035 mg, and 1 mg/0.035 mg. 781 Chestnut Ridge Rd., P.O. Box 4310, Morgantown,
WV 26504.
ANDA 200488 ......... Norethindrone and Ethinyl Estradiol Tablets USP, 0.5 mg/ Do.
0.035 mg.
ANDA 200489 ......... Norethindrone and Ethinyl Estradiol Tablets USP, 1 mg/ Do.
0.035 mg.
ANDA 201250 ......... Vancomycin HCl for Injection USP, EQ 5 g base/vial and Teva Pharmaceuticals USA, Inc.
EQ 10 g base/vial (Pharmacy Bulk Package).
ANDA 201251 ......... Vancomycin HCl for Injection USP, EQ 500 mg base/vial Do.
and EQ 1 g base/vial.
ANDA 201828 ......... Norgestrel and Ethinyl Estradiol Tablets USP, 0.3 mg/0.03 Mylan Laboratories, Ltd.
mg.
ANDA 202203 ......... Topotecan HCl for Injection, EQ 4 mg base/vial .................. Sun Pharmaceutical Industries, Ltd.
ANDA 202746 ......... Zoledronic Acid Injection, EQ 4 mg base/5 mL .................... Sun Pharma Global FZE, c/o Sun Pharmaceutical Indus-
tries, Inc., 2 Independence Way, Princeton, NJ 08540.
ANDA 202875 ......... Norgestrel and Ethinyl Estradiol Tablets USP, 0.5 mg/0.05 Mylan Laboratories, Ltd.
mg.
ANDA 203476 ......... Zolmitriptan Tablets, 2.5 mg and 5 mg ................................. Sun Pharma Global FZE.
ANDA 203685 ......... Irbesartan Tablets USP, 75 mg, 150 mg, and 300 mg ......... Ajanta Pharma Ltd., c/o Ajanta Pharma USA, Inc., One
Grande Commons, 440 US Highway 22 East, Suite 150,
Bridgewater, NJ 08807.
ANDA 203838 ......... Hydrocodone Bitartrate, Chlorpheniramine Maleate, and Tris Pharma, Inc., 2033 Route 130, Monmouth Junction, NJ
Pseudoephedrine HCl Oral Solution, 5 mg/4 mg/60 mg 08852.
per 5 mL.
ANDA 203839 ......... Hydrocodone Bitartrate and Pseudoephedrine HCl Oral So- Do.
lution, 5 mg/60 mg per 5 mL.
Therefore, approval of the Dated: November 27, 2017. Wednesday, January 10, 2018: 8:45
applications listed in table 1 of this Leslie Kux, a.m.–3:00 p.m. ET
document, and all amendments and Associate Commissioner for Policy.. Place: U.S. Department of Health and
supplements thereto, is hereby [FR Doc. 2017–25920 Filed 11–30–17; 8:45 am] Human Services, Hubert H. Humphrey
withdrawn as of January 2, 2018. BILLING CODE 4164–01–P Building, 200 Independence Avenue
Introduction or delivery for introduction SW., Rm. 705A, Washington, DC 20201.
into interstate commerce of products Status: Open.
without approved new drug DEPARTMENT OF HEALTH AND Purpose: At the January 9–10, 2018
applications violates section 301(a) and HUMAN SERVICES full meeting, the Committee will hear
(d) of the Federal Food, Drug, and presentations, hold discussions on
National Committee on Vital and Health several health data policy topics and
Cosmetic Act (21 U.S.C. 331(a) and (d)).
Statistics: Teleconference begin work on activities outlined in the
Drug products that are listed in table 1
that are in inventory on the date that Pursuant to the Federal Advisory NCVHS 2018 workplan. An
this notice becomes effective (see the Committee Act, the Department of environmental scan report will be
DATES section) may continue to be Health and Human Services (HHS) reviewed and discussed by the full
Committee as part of the Health
sradovich on DSK3GMQ082PROD with NOTICES
dispensed until the inventories have announces the following advisory
been depleted or the drug products have committee meeting. Information Privacy and Security
reached their expiration dates or Name: National Committee on Vital Beyond HIPAA project. This effort
otherwise become violative, whichever and Health Statistics (NCVHS), Full includes an exploration of challenges
occurs first. Committee Meeting. that extend beyond HIPAA and the
Dates and Times: range of policy options that may be
Tuesday, January 9, 2018: 9:00 a.m.– available to the Department related to
5:30 p.m. ET privacy, security and access measures to
VerDate Sep<11>2014 16:44 Nov 30, 2017 Jkt 244001 PO 00000 Frm 00038 Fmt 4703 Sfmt 4703 E:\FR\FM\01DEN1.SGM 01DEN1](https://thefederalregister.org/doc/82_FR_57206/page/3.svg)
Document Created: 2018-10-25 10:44:25
Document Modified: 2018-10-25 10:44:25
| Category | Regulatory Information | |
| Collection | Federal Register | |
| sudoc Class | AE 2.7: GS 4.107: AE 2.106: | |
| Publisher | Office of the Federal Register, National Archives and Records Administration | |
| Section | Notices | |
| Action | Notice. | |
| Dates | Approval is withdrawn as of January 2, 2018. | |
| Contact | Trang Tran, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 75, Rm. 1671, Silver Spring, MD 20993-0002, 240-402-7945. | |
| FR Citation | 82 FR 56976 |
2025 Federal Register | Disclaimer | Privacy Policy
USC | CFR | eCFR